
Sanna Timonen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6290495/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Multiâ€modal metaâ€analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. Molecular Systems Biology, 2021, 17, e9526.	7.2	8
2	Regression plane concept for analysing continuous cellular processes with machine learning. Nature Communications, 2021, 12, 2532.	12.8	8
3	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	6.4	28
4	Improved detection of differentially represented DNA barcodes for highâ€ŧhroughput clonal phenomics. Molecular Systems Biology, 2020, 16, e9195.	7.2	15
5	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. PLoS Computational Biology, 2020, 16, e1007604.	3.2	43
6	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
7	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
8	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
9	SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. , 2020, 16, e1007604.		0
10	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. Npj Systems Biology and Applications, 2019, 5, 20.	3.0	32
11	Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies. Cell Chemical Biology, 2019, 26, 1608-1622.e6.	5.2	14
12	JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL. Cancers, 2019, 11, 1833.	3.7	38
13	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. Cancer Research, 2018, 78, 2407-2418.	0.9	60
14	Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors. PLoS Computational Biology, 2017, 13, e1005678.	3.2	84
15	The impact of low-frequency and rare variants on lipid levels. Nature Genetics, 2015, 47, 589-597.	21.4	310